Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 22, 2005New England Journal of MedicineOpen Access

Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAlessandra MangiaCasa Sollievo della SofferenzaRSRosanna SantoroCreighton UniversityNMNicola MinervaNational Agency for New Technologies, Energy and Sustainable Economic Development

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mangia et al. (2005) studied this question.

synapsesocial.com/papers/6a1558ff9b87f33fc69f78adhttps://doi.org/10.1056/nejmoa042608
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy2006 · 469 citations
  2. 2Hepatitis C infection and the patient with end-stage renal disease2002 · 411 citations